Placental MSC therapy shows clinical benefit (improved skin scores, hand function, quality of life) in approximately 60–70% of treated participants. HSCT achieves sustained skin improvement in 70–80% of carefully selected patients, with some achieving reversal of established fibrosis. Success is higher in early-stage, diffuse cutaneous disease than in late-stage or limited forms.
Forty-two completed trials and 7 currently recruiting trials are registered for systemic sclerosis, with diverse cell sources (placental MSC predominating, alongside autologous bone-marrow-derived MSC and HSCT). HSCT trials have shown arrest or reversal of skin fibrosis in approximately 70–80% of treated patients, with sustained benefit at 5-year follow-up in many, though the treatment carries significant morbidity (infection risk, infertility, relapse). MSC trials are smaller and earlier-stage; published data show stabilisation of skin thickening (modified Rodnan skin score stability or improvement) in 50–70% of placental MSC-treated participants over 6–24 months, often accompanied by improved lung function and hand mobility.
Am I a candidate? → · Scleroderma (Systemic Sclerosis): full overview → · Scleroderma (Systemic Sclerosis) cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite